Despite growing number of animal studies suggesting beneficial effects of IL-6 suppression in DKD and CKD, clinical experience with inhibitors of IL-6 pathways in diabetic patients are rather limited and less conclusive (Table 2B). The gene discussed is IL6; the disease is diabetic kidney disease.